Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240339 | 0.98 | SLC6A3 (0.60) | SLC6A3SLC6A4HSD11B1SLC6A2CACNA1G | |
| SCHEMBL6208716 | 0.86 | SLC6A4 (0.65) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6492041 | 0.84 | SLC6A4 (0.68) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6231738 | 0.84 | SLC6A3 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6494934 | 0.82 | SLC6A4 (0.63) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6209359 | 0.79 | LMNA (0.51) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6208320 | 0.78 | LMNA (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7573036 | 0.75 | SOAT2 (0.51) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17832228 | 0.75 | SLC6A4 (0.96) | SLC6A3SLC6A4HSD11B1SLC6A2 | |
| SCHEMBL3518031 | 0.73 | SLC6A4 (1.00) | SLC6A3SLC6A4HSD11B1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | SLC6A3 3645/4885SLC6A4 3525/4885HSD11B1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.